New drug Camzyos can be prescribed at hospitals

Passed the DC of medical institutions such as Sinchon Severance Hospital

EXPLORER-HCM research demonstrates improved motor skills

The new drug Camzyos for obstructive hypersatic myocardial infarction is entering the general hospital prescription.

 

According to the related industry, Camzyos of BMS Pharmaceutical Korea has passed the Drug Committee (DC) of medical institutions such as SMC and Sinchon Severance Hospital.

 

Camzyos is the first and only treatment that selectively inhibits the excessive cross-bining of cardiac myosine and acttin, the cause of obstructive hypertrophic cardiomyopathy (oHCM).

 

The drug has the mechanism of separating myosine from actin and relaxing the excessively contracted heart muscle, improving occlusion with an inflated left ventricle structure and left ventricle leaks.

 

The clinical trial based on the Camzyos permit is the EXPLORER-HCM study.

 

In the trial, Camzyos improved more than twice as much as the patient's symptoms (NYHA grade) and motor performance (maximal oxygen intake, pVO2), which is a primary evaluation variable.

 

Of these, 20% of the Camzyos dosing group achieved both NYHA ratings and pVO2 improvements.

 

After exercise, the left ventricle also reduced the occlusion index more than fourfold.

 

Seven out of 10 people treated wit Camzyos had improved their indicators to such an extent that they did not consider surgery, maintaining a consistent effect for 30 weeks.

 

oHCM is a rare heart disease in which the left Ventil muscle of the heart is abnormally thickened and blocks blood flow through the entire body through the aorta.

 

Symptoms of oHCM vary, including shortness of breath, dizziness, chest pain, which can increase the risk of various cardiovascular complications such as heart failure and atrial fibrillation.

 

Currently, oHCM treatment focuses on symptom relief and management rather than underlying treatment, so there was a high demand for unfulfilled treatment.

 

Drug treatment options such as beta blockers and calcium channel blockers could reduce heart rate and myocardial contractility, but there were limitations that existing drug treatment options alone made it difficult to expect long-term improvement.

 

Professor Lee Sang-cheol of the Department of Circulation at Samsung Seoul Hospital said, "OHCM is a rare disease that can cause sudden heart death without warning, and there has been many difficulties in treatment because there is no effective way to treat it non-invasively.

 

Camzyos expects to be able to restore patients' quality of life by taking oral doses once a day, with excellent symptom-improving effects from the early days of treatment."